HCPCS Level II code A9602 designates fluorodopa F-18 supplied for diagnostic use and billed per millicurie. Fluorodopa F-18 is a PET radiopharmaceutical used in diagnostic imaging to evaluate dopaminergic function and related neurologic conditions; accurate coding affects billing, utilization tracking, and access to specialized imaging services nationwide. This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare to provide a national perspective on coverage and reimbursement practices.

Readers will find a concise overview of what the code represents, the typical clinical and service settings where it is used, and which payers are included in the review. The publication summarizes available benchmarks and policy context relevant to radiopharmaceutical billing, highlights common billing considerations for per-millicurie radiotracers, and outlines areas where payers and Medicare may apply specific coverage rules or prior authorization processes. Data not provided in the input are noted where applicable. The focus is national policy and billing context rather than state-specific rules or clinical recommendations.